Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage II, III or IV melanoma patients.~* Tumor expression of Melan-A.~* Human leukocyte antigen-A2 (HLA-A2) positive.~* Expected survival of at list 3 months.~* Karnofsky scale performance status of 70 % or more.~* Age ≥ 18 years.~* Able to give a written informed consent.~* The following laboratory results:~Hemoglobin ≥ 100g/L, Neutrophil count ≥ 1.5 x 109/L, Lymphocyte count ≥ 0.5 x 109/L, Platelet count ≥ 100 x 109/L, Serum creatinine ≤ 2 mg/dL (0.18mmol/L), Serum bilirubin ≤ 2mg/dL (0.034mmol/L), Granulocyte count \> 2.5x109/L, Aspartate Amino Transférase (ASAT), Alanine Amino Transferase (ALAT) \< 2.5 x upper limit of normal, Activated Partial Thromboplastin Time (aPTT) within the normal ranges ±25%, Thromplastin (TP) ≥ 80%~Exclusion Criteria:~* Clinically significant heart disease.~* Serious illness, eg. serious infections requiring antibiotics, uncontrolled peptic ulcer, or central nervous system disorders.~* History of immunodeficiency disease or autoimmune disease.~* Metastatic disease to the central nervous system, unless treated and stable.~* Known HIV positivity.~* Known seropositivity for hepatitis B surface antigen.~* Concomitant treatment with steroids, antihistamine drugs. Topical or inhalation steroids are permitted.~* Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.~* Pregnancy or lactation.~* Women of childbearing potential not using a medically acceptable means of contraception.~* Psychiatric or addictive disorders that may compromise the ability to give informed consent.~* Lack of availability of the patient for immunological and clinical follow-up assessment.~* Coagulation or bleeding disorders.~* Kidney dysfunction with creatinine \> 2 X the upper limit of the normal value.~* Reported strong (allergic) reactions to previous vaccination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 vaccine injections in 1 limb (Type: EXPERIMENTAL): 9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
- 2 vaccine injections in distinct limbs (Type: EXPERIMENTAL): Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
- 2 vaccine injections in distinct limbs (Type: EXPERIMENTAL): Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)

Based on this trial design, predict the completion outcome and termination type (if applicable).